Jun 2015,Proprium Published an article entitled “CHI3L1 IS a Liver-Enriched,Noninvasive Biomarker That Can Be Used to Staqe and Diaqnose Substantial Hepatic Fibrosis” on OMICS: A Journal of Integrative Biology.
According to several international and Chineseguidelines for the treatment of chronic liver diseases, including HBVinfection, accurate determination offibrosis stages iscritical foroptimizing the timing of antiviral treatment . In a study conducted at ZhejiangProvincial People's Hospital, the first Affiliated Hospital of ZhejiangUniversity and the Second Affiliated Hospital of ZhejiangUniversity, Hangzhou,China, 92 biopsy-confirmed stage S0 and S1 liver fibrosis patients, 31biopsy-confirmed stage S2 liver fibrosis patients and 153 advanced stage liverfibrosis (S3-S4) were enrolled. The median levels of serum CHI3L1 is 46.3 withthe upper 95% CI at 50.4 for stage S0-1 and 56.8 with the upper 95% CI at 76.2for S2 liver fibrosis (Table 2). A cutoff value of 76.2 could beused toidentify liver fibrosis at stage S2 or less. The differences between stage S0_1and S2 patients, and between stage S2 and S3_4 patients are both statisticalsignificant (P<0.05, the Mann-Whitney test).
This achievement provesthegeneral hope people development capabilities, will be the majority ofpatients with liver disease gospel. Proprium welcomed the attention andcooperation of all walks of life.